Indo-Bangla Pharmaceuticals

Indo-Bangla Pharmaceuticals is a Bangladesh-based commercial generic drug manufacturer and marketer focused on human health products. The company traces its roots to 1954, later operating as Indo-Pak Pharmaceutical Works before being incorporated as Indo-Bangla Pharmaceuticals Limited in 2014 and listing on the Dhaka Stock Exchange in 2018. It manufactures, markets, and distributes non-antibiotic generic medicines and related medical preparations across multiple dosage forms including tablets, capsules, syrups, oral saline, and suspensions. Public sources describe a broad portfolio spanning analgesic, gastrointestinal, respiratory, cardiovascular, central nervous system, dermatology, and other therapeutic categories, with products such as omeprazole, esomeprazole, dexamethasone, domperidone, metronidazole, montelukast, paracetamol, and sildenafil citrate. The company appears to be a fully commercial-stage pharmaceutical business rather than a clinical-stage biotech developer, and no proprietary R&D pipeline was clearly disclosed in the sources reviewed.